Literature DB >> 5007842

Effect of rifampicin and isoniazid on liver function.

S Lal, S N Singhal, D M Burley, G Crossley.   

Abstract

The effects of rifampicin and isoniazid on liver function have been studied in 63 patients with pulmonary tuberculosis; 29% showed abnormalities of serum aspartate aminotransferase (SGOT) and a similar percentage abnormalities of serum bilirubin. These usually occurred during the first 12 weeks of therapy. The average duration of the abnormalities was 14(1/2) days, irrespective of whether treatment was interrupted or not.The relationship between raised SGOT and acetylator phenotype in a small number of patients suggests that those with raised SGOT are usually slow acetylator phenotypes. It seems that hepatic reactions in patients with previously normal liver function are usually mild and non-specific. However, patients who continue with rifampicin should be kept under close biochemical observation.

Entities:  

Mesh:

Substances:

Year:  1972        PMID: 5007842      PMCID: PMC1787114          DOI: 10.1136/bmj.1.5793.148

Source DB:  PubMed          Journal:  Br Med J        ISSN: 0007-1447


  16 in total

1.  A cooperative study on rifampicin in original treatment of advanced pulmonary tuberculosis.

Authors:  A Gyselen; L Verbist; J Cosemans; L M Lacquet; J Prignot; F Simon-Pouthier; R Debrabandere; J Devriendt
Journal:  Acta Tuberc Pneumol Belg       Date:  1969

2.  Clinical studies with a new rifamycin derivative.

Authors:  H D Cohn
Journal:  J Clin Pharmacol J New Drugs       Date:  1969 Mar-Apr

3.  The rifamycins with other drugs in the treatment of pulmonary tuberculosis: a report of nine cases.

Authors:  A Pines; H Raafat; R Bundi
Journal:  Tubercle       Date:  1967-12

4.  Some comparative aspects of rifampicin and isoniazid.

Authors:  G Canetti; M Le Lirzin; G Porven; N Rist; F Grumbach
Journal:  Tubercle       Date:  1968-12

5.  Antituberculous activity of rifampin in vitro and in vivo and the concentrations attained in human blood.

Authors:  L Verbist; A Gyselen
Journal:  Am Rev Respir Dis       Date:  1968-12

6.  Serum transaminase elevations and other hepatic abnormalities in patients receiving isoniazid.

Authors:  L Scharer; J P Smith
Journal:  Ann Intern Med       Date:  1969-12       Impact factor: 25.391

7.  [Hepato-biliary effects of the combination rifampicin-isoniazid. I. Histological study in rats].

Authors:  F C Hugues; C Marche; J Marche
Journal:  Therapie       Date:  1969 Sep-Oct       Impact factor: 2.070

8.  [Jaundice during treatment with rifampicin (12 cases)].

Authors:  R Lesobre; J Ruffino; L Teyssier; F Achard; G Brefort
Journal:  Rev Tuberc Pneumol (Paris)       Date:  1969 Apr-May

9.  Jaundice after rifampicin.

Authors:  A W Lees; B Asgher; M A Hashem; B N Sinha
Journal:  Br J Dis Chest       Date:  1970-04

10.  [Experimental antitubercular activity of rifampicin, a derivative of rifamycin SV].

Authors:  F Grumbach; N Rist
Journal:  Rev Tuberc Pneumol (Paris)       Date:  1967 Sep-Oct
View more
  11 in total

1.  Hepatotoxicity of antituberculosis drugs.

Authors:  L P Ormerod; C Skinner; J Wales
Journal:  Thorax       Date:  1996-02       Impact factor: 9.139

Review 2.  Mechanisms and prediction of drug-induced liver disease.

Authors:  P Berthelot
Journal:  Gut       Date:  1973-04       Impact factor: 23.059

3.  Serum concentration and half-life of rifampicin after simultaneous oral administration of aminosalicylic acid or isoniazid.

Authors:  G Boman
Journal:  Eur J Clin Pharmacol       Date:  1974       Impact factor: 2.953

4.  Effect of rifampicin in the treatment of pruritus in hepatic cholestasis.

Authors:  G V Gregorio; C S Ball; A P Mowat; G Mieli-Vergani
Journal:  Arch Dis Child       Date:  1993-07       Impact factor: 3.791

Review 5.  Acute liver injury.

Authors:  I C Talbot
Journal:  J Clin Pathol Suppl (R Coll Pathol)       Date:  1975

6.  Adverse effects of antituberculosis drugs.

Authors:  D J Girling
Journal:  Drugs       Date:  1982 Jan-Feb       Impact factor: 9.546

Review 7.  Drug-induced chronic hepatitis.

Authors:  R Wright
Journal:  Springer Semin Immunopathol       Date:  1980-12

8.  Antituberculosis treatment-induced hepatotoxicity: role of predictive factors.

Authors:  J Singh; A Arora; P K Garg; V S Thakur; J N Pande; R K Tandon
Journal:  Postgrad Med J       Date:  1995-06       Impact factor: 2.401

9.  Hepatotoxicity of rifampicin and isoniazid in children treated for tuberculosis.

Authors:  O Linna; M Uhari
Journal:  Eur J Pediatr       Date:  1980-09       Impact factor: 3.183

Review 10.  Clinical pharmacokinetics of isoniazid.

Authors:  W W Weber; D W Hein
Journal:  Clin Pharmacokinet       Date:  1979 Nov-Dec       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.